Bio-Rad Laboratories

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

Retrieved on: 
четверг, мая 30, 2024
Partnership, Patient, DNA, Booth, B cell, Clinical trial, Recurrence, FDA, Disease, AMR, Medical school, OCX, Research, CD38, CSO, Bio-Rad Laboratories, Medical University of Vienna, Invention, Q&A, Charité, Physician, Role, Kidney, PCR, Pharmaceutical industry

Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study.

Key Points: 
  • Ekke Schuetz and Julia Beck, inventors of the technology, are among the authors of the study.
  • VitaGraft Kidney was used to monitor graft injury in a phase 2 double-blind, placebo-controlled study ( NCT05021484 ) of the investigational drug felzartamab, a fully human CD38 monoclonal antibody, for antibody-mediated rejection (AMR), a leading cause of kidney allograft failure.
  • VitaGraft Kidney measures the amount of DNA in transplant patients’ blood that comes from the donor organ, a key biomarker for assessing graft health.
  • This process is commonly referred to as donor-derived cell-free DNA (dd-cfDNA) testing and is widely used in clinical practice today.

Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group

Retrieved on: 
четверг, мая 30, 2024
Medical Supplies, Health, Health Technology, Research, Science, Biotechnology, Chemical engineering, Danaher Corporation, AB, Bachelor, Microbiology, Marketing, Senior, Polymer, Bio-Rad Laboratories, Acquisition, BioMérieux, Royal Society Te Apārangi, Royal institute, Management

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024.
  • Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher Corporation and a leading global molecular diagnostics company.
  • While at Cepheid, Ms. Engelhardt was Senior Vice President and General Manager overseeing the emerging growth opportunities business, as well as Senior Vice President of global research and development, strategy, product management and marketing functions supporting the company’s extensive product portfolio.
  • “We are very pleased to welcome Anette Engelhardt as President of our Clinical Diagnostics Group,” stated Andy Last, Bio-Rad’s Executive Vice President and Chief Operating Officer.

Oncocyte Reports First Quarter 2024 Financial Results

Retrieved on: 
среда, мая 15, 2024
Insurance, Security (finance), Partnership, RUO, FDA, Telephone, Marketing, Bio-Rad Laboratories, OCX, Research, Therapy, IVD

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

Key Points: 
  • IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.
  • “In the first quarter of 2024, Oncocyte made significant progress toward commercializing its innovative blood-based diagnostic tests.
  • For Oncocyte’s complete financial results for the first quarter ended March 31, 2024, see the Company’s quarterly Form 10-Q to be filed with the Securities and Exchange Commission on May 15, 2024.
  • Oncocyte will host a conference call to discuss first quarter 2024 financial results after market close on Wednesday, May 15, 2024 at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Bio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference

Retrieved on: 
четверг, мая 23, 2024
Diabetes, Other Health, Finance, Stem Cells, Pharmaceutical, Professional Services, Medical Devices, Infectious Diseases, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Medical Supplies, Bio-Rad Laboratories, Conference

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 10:30 AM Eastern Time (7:30 AM Pacific Time).

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 10:30 AM Eastern Time (7:30 AM Pacific Time).

Labroots Announces the 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024

Retrieved on: 
четверг, мая 9, 2024
Singular, Labroots, Genetics, Genomics, DSM-IV codes, Mass, Networking hardware, Travel, Health, QIAGEN, Doctor of Philosophy, Research, Gene, Scale, NGS, Knowledge, Entrepreneurship, Future, Bio-Rad Laboratories, Algorithm, Diagnosis, History, MPH, Harvard Medical School, Mass General Brigham, Genetic testing, Thermo Fisher Scientific, Vaccine

YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series. This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.

Key Points: 
  • Join Labroots on May 15, 2024, for the 12th Annual Precision Medicine Virtual Event Series, exploring the latest in genomics, genetics, and molecular diagnostics, with keynote speakers, dynamic sessions, and opportunities for continuing education.
  • YORBA LINDA, Calif., May 9, 2024 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website and producer of educational virtual events and webinars, proudly announces the upcoming 12th Annual Precision Medicine Virtual Event Series .
  • This premier virtual conference, scheduled for May 15, 2024, invites worldwide experts and enthusiasts to explore the latest innovations and advancements in precision medicine.
  • This year's event will dive deep into the cutting-edge areas of genomics, genetics, and molecular diagnostics, pivotal in the ongoing revolution of personalized healthcare.

Bio-Rad Reports First-Quarter 2024 Financial Results

Retrieved on: 
вторник, мая 7, 2024
Biotechnology, Diabetes, Health, Other Health, Pharmaceutical, Stem Cells, Research, Medical Devices, Infectious Diseases, General Health, Science, COVID-19, Clinical Trials, Medical Supplies, Acquisition, Table, Webcast, Bank statement, Forecasting, Nature, GAAP, Growth, EPS, Bio-Rad Laboratories, Bank

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Key Points: 
  • A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
  • Management will discuss the company’s first quarter 2024 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on May 7, 2024.
  • There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies.
  • The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.

Europe In-Vitro Diagnostics (IVD) Market Insights 2024-2029: Increasing Adoption of Automation in Laboratories, Growing Importance for Personalised Medicine - ResearchAndMarkets.com

Retrieved on: 
понедельник, мая 6, 2024
Health, Biotechnology, Conditional sentence, EP, Pandemic, Automation, Risk, Thermo Fisher Scientific, Hematology, Siemens Healthineers, Research, Calibration, Abbott Laboratories, Infection, Partnership, Bio-Rad Laboratories, Documentation, 2005 in television, Medicine, Diagnosis, Ageing, Diabetes, Molecular biology, COVID-19, IVD, Growth, Prevalence, Medical device

Europe's in-vitro diagnostics (IVDs) market is expected to grow at a CAGR of 2.23% from 2023 to 2029.

Key Points: 
  • Europe's in-vitro diagnostics (IVDs) market is expected to grow at a CAGR of 2.23% from 2023 to 2029.
  • Vendors in the market are increasing their market share through inorganic growth.
  • Spain shows the highest growth rate, with a CAGR of 3% in Europe's in-vitro diagnostics (IVDs) market.
  • By end-user, the standard reference labs segment dominated the market share of the Europe in-vitro diagnostics (IVDs) market.

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
пятница, мая 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032

Retrieved on: 
пятница, мая 3, 2024
PFS, United Nations, FDA, Mutation, Daiichi Sankyo, Pancreatic cancer, Bio-Rad Laboratories, MBC, ONC, Prostate cancer, Paper, Behavior, Breast cancer, AstraZeneca, Paclitaxel, Fast track (FDA), Woman, TSX, CELC, DdPCR, Oncolytics Biotech, Ageing, Therapy, Pelareorep, Combination therapy, Combination, Mutant, Survival, Research, Cancer, MRD, Progression-free survival, Marketing, Immunotherapy, AHN, PCR, United, Patient, Type, Pharmaceutical industry

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- According to a "highly troubling" new study, the rising number of cancer cases in young people is being attributed to "accelerated aging." Further alarm is being spread by the United Nations, whose health authorities are predicting global cancer cases to rise around 77% by 2050, with richer countries expected to have the greatest absolute increase in cancer, with an additional 4.8 million new cases predicted in 2050. With the global cancer immunotherapy market projected by analysts at Custom Market Insights to reach US$314.4 billion by 2032, growing at a 7.2% CAGR, the biotech sector continues to make significant developments in cancer treatment and diagnostics, with recent updates coming from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Celcuity Inc. (NASDAQ: CELC), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), Bio-Rad Laboratories, Inc. (NYSE: BIO), and AstraZeneca PLC (NASDAQ: AZN).

Key Points: 
  • "A key focus for Oncolytics in 2024 is defining the regulatory path for pelareorep in breast cancer treatment," said Matt Coffey, President and CEO of Oncolytics.
  • "We are optimistic that pelareorep, in combination with paclitaxel, could significantly enhance clinical outcomes for patients with HR+/HER2- metastatic breast cancer.
  • Oncolytics Biotech requested to meet with the FDA in Q2 2024 to finalize the registrational trial design and objectives for using pelareorep to treat metastatic breast cancer.
  • "These data underscore the potential for treatment with ENHERTU across the spectrum of HR-positive breast cancer, further redefining the treatment of metastatic breast cancer."

Seven Corporate Buyers Enter Into Aggregation Deal To Purchase 180 MW of Solar Energy Through the Net Zero Consortium for Buyers

Retrieved on: 
среда, мая 1, 2024
Negotiation, Sustainable business, Cisco, Sustainability, Laboratory, Health, Software, Partnership, Electricity, ERCOT, Research, VPPA, Gamer, Bio-Rad Laboratories, Idexx Laboratories, Duke Energy, Multimedia, Cadence Design Systems, PTC, Renewable energy

The seven buyers signed VPPAs to develop new renewable energy capacity in the ERCOT region of Texas through SR Inc's NZCB.

Key Points: 
  • The seven buyers signed VPPAs to develop new renewable energy capacity in the ERCOT region of Texas through SR Inc's NZCB.
  • The buyer-aggregated approach democratizes access to the commercial and environmental benefits of utility-scale renewable energy by making procurement accessible to a broader range of enterprises.
  • Finally, a large healthcare company will purchase renewable energy generated from the remaining 20 MW portion of Millers Branch.
  • SR Inc's Net Zero Consortium for Buyers (NZCB) is a confidential buyers' community committed to creating corporate buyer-favorable renewable energy transactions that enable participating enterprises to chart a profitable path to Net Zero emissions globally.